Argenx receives positive chmp opinion for efgartigimod for the treatment of adult patients with generalized myasthenia gravis in europe

Breda, the netherlands— june 24 , 2022—argenx (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended european commission (ec) approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody positive.
ARGX Ratings Summary
ARGX Quant Ranking